Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369590 · ClinicalTrials.gov registry record · Phase 2
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00369590: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00369590 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00369590, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent malignant or anaplastic gliomas that did not respond to temozolomide. VEGF Trap may stop the growth of malignant or anaplastic gliomas by blocking blood flow to the tumor.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- BIOLOGICAL ziv-aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369590
The ClinicalTrials.gov registry entry for NCT00369590 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00369590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369590 about?
NCT00369590 is a clinical study titled "VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide". This phase II trial is studying how well VEGF Trap works in treating patients with recurrent malignant or anaplastic gliomas that did not respond to temozolomide. VEGF Trap may stop the growth of malignant or anaplastic gliomas by blocking blood flow to the tumor.
What is the current status of trial NCT00369590?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2006-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00369590?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), ziv-aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00369590?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.